Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns

IL-17 and IL-23 inhibitors, used for treating moderate-to-severe psoriasis and other inflammatory diseases, can cause a range of cutaneous adverse reactions. These reactions include common psoriasiform and eczematous eruptions, as well as less frequent conditions like lupus-like syndromes and bullous pemphigoid. The mechanisms are thought to involve changes in immune signaling rather than direct drug toxicity. Management depends on the severity and type of reaction, with options ranging from topical treatments to discontinuation of the drug. Recognizing these reactions is crucial due to their similarity to primary dermatologic diseases, and further research is needed to better understand their incidence and management.